{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Shaw RH"],"funding":["Medical Research Council","National Institute for Health Research (NIHR)"],"pagination":["1049-1060"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9179150"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["10(11)"],"pubmed_abstract":["<h4>Background</h4>Priming COVID-19 vaccine schedules have been deployed at variable intervals globally, which might influence immune persistence and the relative importance of third-dose booster programmes. Here, we report exploratory analyses from the Com-COV trial, assessing the effect of 4-week versus 12-week priming intervals on reactogenicity and the persistence of immune response up to 6 months after homologous and heterologous priming schedules using the vaccines BNT162b2 (tozinameran, Pfizer/BioNTech) and ChAdOx1 nCoV-19 (AstraZeneca).<h4>Methods</h4>Com-COV was a participant-masked, randomised immunogenicity trial. For these exploratory analyses, we used the trial's general cohort, in which adults aged 50 years or older were randomly assigned to four homologous and four heterolog"],"journal":["The Lancet. Respiratory medicine"],"pubmed_title":["Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial."],"pmcid":["PMC9179150"],"funding_grant_id":["MR/N013204/1","NF-SI-0617-10010","NIHR201409","MR/N026993/1"],"pubmed_authors":["Ferreira DM","Nguyen-Van-Tam JS","Walker LL","Yao XL","Warren S","Rampling T","Howe EG","Mujadidi YF","Turner PJ","Okenyi E","Heath PT","Charlton S","Hultin C","Ricamara M","Brown CH","Maelin F","Bula M","Clutterbuck EA","Singh N","Lazarus R","Hughes E","Com-COV Study Group","Hill H","Bartholomew J","Yee Ting NY","Shaw RH","Lambe T","Presland L","Royal S","Finn A","San Francisco Ramos A","Screaton GR","Green CA","Naker K","Ramasamy MN","Noristani R","Andrews NJ","Libri V","Varkonyi-Clifford S","Saich S","Qureshi E","Desai A","Belton S","Provstgaard-Morys S","Horswill S","Kellett Wright JK","Fyles F","Faust SN","Whittley S","Greenland M","Oldfield NJ","Long F","Carson A","Dejnirattisai W","Ramsay M","Read RC","Burhan H","Di Maso C","Cameron JC","White R","Liu X","Snape MD","Galiza EP","Crook R","Hammersley D","Turner N","Hallis B","Plested EL","Dinesh T","Collins AM","Mead G","Stuart ASV","Robinson H","Riaz T","Munro APS","Ghulam Farooq M","Turner DPJ","Adams K","Gokani K","Morey ER","Vichos I","Williams RL","Aley PK","Penciu FD"],"additional_accession":[]},"is_claimable":false,"name":"Effect of priming interval on reactogenicity, peak immunological response, and waning after homologous and heterologous COVID-19 vaccine schedules: exploratory analyses of Com-COV, a randomised control trial.","description":"<h4>Background</h4>Priming COVID-19 vaccine schedules have been deployed at variable intervals globally, which might influence immune persistence and the relative importance of third-dose booster programmes. Here, we report exploratory analyses from the Com-COV trial, assessing the effect of 4-week versus 12-week priming intervals on reactogenicity and the persistence of immune response up to 6 months after homologous and heterologous priming schedules using the vaccines BNT162b2 (tozinameran, Pfizer/BioNTech) and ChAdOx1 nCoV-19 (AstraZeneca).<h4>Methods</h4>Com-COV was a participant-masked, randomised immunogenicity trial. For these exploratory analyses, we used the trial's general cohort, in which adults aged 50 years or older were randomly assigned to four homologous and four heterolog","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2026-05-09T15:11:56.052Z","creation":"2024-10-15T13:35:11.769Z"},"accession":"S-EPMC9179150","cross_references":{"pubmed":["35690076"],"doi":["10.1016/S2213-2600(22)00163-1"]}}